Indoco Remedies Limited (NSE:INDOCO)
India · Delayed Price · Currency is INR | Market Cap | 20.36B -23.3% |
| Revenue (ttm) | 18.73B +12.1% |
| Net Income | 56.30M |
| EPS | 0.63 |
| Shares Out | 92.30M |
| PE Ratio | 349.16 |
| Forward PE | 51.42 |
| Dividend | 0.20 (0.09%) |
| Ex-Dividend Date | Sep 10, 2026 |
| Volume | 92,532 |
| Open | 225.60 |
| Previous Close | 225.60 |
| Day's Range | 216.00 - 225.70 |
| 52-Week Range | 162.19 - 291.00 |
| Beta | 0.62 |
| Analysts | Hold |
| Price Target | 264.00 (+19.7%) |
| Earnings Date | Oct 27, 2026 |
About Indoco Remedies
Indoco Remedies Limited manufactures and markets formulations and active pharmaceutical ingredients in India and internationally. It offers products for gastrointestinal, anti-infectives, respiratory, stomatological, vitamins/minerals/nutrients, urological, ophthal/ontological, dermatology, pain/analgesic, cardiac, anti-diabetic, and gynaecological therapeutic areas. The company also provides branded generics comprising analgesic tablets and topical preparations; anti-hypertensive; protein supplements; multivitamin tablets and syrups; antibioti... [Read more]
Financial Performance
In fiscal year 2026, Indoco Remedies's revenue was 18.45 billion, an increase of 10.84% compared to the previous year's 16.65 billion. Losses were -951.36 million, 29.0% more than in 2025.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for INDOCO stock is "Hold." The 12-month stock price target is ₹264.00, which is an increase of 19.70% from the latest price.
News
Indoco Remedies Share Price Quietly Does Something Most Mid-Cap Pharma Stocks Won’t
Financial headlines are not typically dominated by Indoco Remedies. Its market capitalization of about ₹2,200 crore keeps it firmly in mid-cap territory, where stocks can move sharply on relatively mo...
Indoco Remedies Transcript: Q1 26/27
Revenue and EBITDA margins improved year-over-year, driven by strong U.S. and API growth, while domestic and European businesses remained steady despite external challenges. Operational efficiencies, cost controls, and regulatory approvals support a positive outlook, with double-digit growth and margin expansion targeted.
Indoco Remedies Quarterly report: Q1 2027
Indoco Remedies has published its Q1 2027 quarterly earnings report on July 28, 2026.
Pharma sector stocks up today, June 29: Dr. Reddy's Lab jumps 4.11%, Indoco Remedies rises 2.63%, Strides Pharma up 2.70%
The pharmaceutical sector showed mixed movement in early trading on June 29, 2026. The S&P BSE Healthcare index rose 0.84% to 48,967.73 points, while the broader market remained nearly flat…
Indoco Remedies Goa plant receives EU GMP certification from Malta Medicines Authority
Indoco Remedies Ltd. has announced that its Goa manufacturing facility has successfully cleared an inspection by the Malta Medicines Authority. The inspection, which took place from November 19 to Nov...
Pharma sector stocks trade mixed on June 22: Cipla up 2.23%, Indoco Remedies gains 2.38%, Wockhardt falls 1.41%
Pharma stocks traded mixed on June 22, 2026, during the early morning session, with gains and losses spread across the sector. The broader market was positive, with the Nifty 50…
Pharma sector stocks today on June 22: Cipla up 2.23%, Indoco Remedies gains 2.38%, Wockhardt falls 1.41%
Pharma stocks traded mixed on June 22, 2026, during the early morning session, with gains and losses spread across the sector. The broader market was positive, with the Nifty 50…
Pharma sector stocks today, June 16: Sudeep Pharma up 3.09%, Panacea Biotech gains 0.89%, Indoco Remedies falls 1.13%
Pharma stocks traded mixed on June 16, 2026, during the early morning session, with modest gains and losses spread across the sector. The broader market was positive, with the Nifty…
Pharma sector stocks surge today, June 11: Wockhardt up 2.41%, Strides Pharma gains 2.10%, Indoco Remedies rises 2.58%
Pharma stocks traded largely in positive territory on June 11, 2026, during the early morning session, with most stocks posting gains even as the broader market remained weak. The Nifty…
Pharma sector stocks today, May 29: Wockhardt jumps 7.40%, Indoco Remedies rises 3.46%, Sudeep Pharma up 3.45%
The pharmaceutical stocks traded mixed on May 29, 2026, during the morning session. While some stocks like Wockhardt, Indoco Remedies, and Sudeep Pharma posted strong gains, a few others saw…
Indoco Remedies receives EU GMP certification for Baddi plant
Indoco Remedies Ltd. has announced that its Oral Solid Dosage (OSD) manufacturing facility at Baddi, Himachal Pradesh, has received EU GMP certification from the German Health Authority (Berlin). The ...
Indoco Remedies completes business transfer to Sunways India
Indoco Remedies has successfully completed the transfer of its ophthalmic business division to Sunways (India) Private Limited. This strategic move, finalised on May 18, 2026, involves the sale and tr...
Indoco Remedies receives EU GMP certification from Malta Medicines Authority
Indoco Remedies Ltd. has successfully obtained EU GMP certification for its manufacturing facility located at Baddi, following an inspection by the Malta Medicines Authority. The inspection took place...
Pharma sector stocks today, May 8: Indoco Remedies falls 6%, Natco Pharma jumps 2.57%, Mankind Pharma up 2.43%
Indian pharmaceutical stocks showed mixed performance in early trading on May 8, 2026. The S&P BSE Healthcare index was up 0.26% at 46,515.42, while the broader market declined, with Nifty…
Indoco Remedies Transcript: Q4 25/26
Q4 saw a strong turnaround with 25.8% YoY standalone revenue growth, led by international formulations, while domestic sales were muted due to seasonality. Debt remains high but is being managed, and no major CapEx is planned. Receivables and forex losses impacted financials.
Indoco Remedies Quarterly report: Q4 2026
Indoco Remedies has published its Q4 2026 quarterly earnings report on May 7, 2026.
Indoco Remedies Annual report: Q4 2026
Indoco Remedies has published its Q4 2026 annual report on May 7, 2026.
Pharma sector stocks today, April 28: Glenmark Pharma surge 1.80%, Strides Pharma down 2%, Indoco Remedies up 1.52%
Indian pharmaceutical stocks opened the session on April 28, 2026, with a mixed tone. The Nifty Pharma Index stood at 23,132.0, down 0.2% in early trade, while the broader S&P BSE Healthcare Index…
Pharma sector stocks surge today, April 15: Indoco Remedies up 5%, Orchid Pharma gains 4.04%, Dr. Reddy's falls 1.64%
Indian pharmaceutical sector stocks traded higher in early morning trade on Tuesday, April 15, 2026, with most counters advancing while Dr. Reddy's Laboratories remained an outlier on the downside. Am...
Indoco Remedies receives USFDA final approval for Brivaracetam Oral Solution 10 mg/mL
Indoco Remedies Ltd. has secured final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug...
Indoco Remedies Transcript: Q3 25/26
Q3 FY26 saw strong export and API growth, improved subsidiary performance, and margin expansion, despite flat domestic sales and non-recurring costs from regulatory issues. Debt reduction and margin improvement are key priorities, with robust growth expected in Europe, OTC, and API segments.
Indoco Remedies Quarterly report: Q3 2026
Indoco Remedies has published its Q3 2026 quarterly earnings report on February 3, 2026.
Indoco Remedies Q3 Results: Revenue rises 8.5% YoY to Rs 445.4 crore, net loss at Rs 29.8 crore
Indoco Remedies reported its Q3 financial results, showing steady growth in revenue and operating profitability on a year-on-year basis, while...
Indoco Remedies Transcript: Q2 25/26
Q2 FY26 saw strong revenue growth and margin recovery, driven by robust India and emerging market performance, new product launches, and operational improvements. USFDA remediation and subsidiary losses remain key risks, but management expects further growth, margin expansion, and limited CapEx ahead.
Indoco Remedies Quarterly report: Q2 2026
Indoco Remedies has published its Q2 2026 quarterly earnings report on November 6, 2025.